SYMLIN™ (pramlintide acetate)Overview

• Target population: People with diabetes using insulin

• Synthetic analog of human amylin

  • ß-cell hormone co-secreted with insulin

• 4,400+ subjects exposed to SYMLIN inover 50 clinical studies

• Substantial safety database

  • Most common side effect reported was mild to moderate, transient nausea

REGULATORYREVIEW

Previous slide

Next slide

Back to first slide

View graphic version